Takeda Acquires LigoCyte Pharma

November 2012
Contract Pharma;Nov/Dec2012, Vol. 14 Issue 9, p94
Trade Publication
The article offers information related to pharmaceutical industry acquisition. It says that LigoCyte Pharmaceuticals Inc. will be acquired by Takeda Pharmaceutical Co. Ltd. as part of the company's expansion for its vaccine business. It mentions that Pfizer Inc. has entered an option and merger agreement with NextWave Pharmaceuticals Inc. It adds that Dr. Reddy's Laboratories Ltd. has offered $36 million to acquire OctoPlus NV located in the Netherlands.


Related Articles

  • Today's Transactions Pfizer Acquires NextWave Pharmaceuticals for up to $700M. COLLINS, ALLISON // Mergers & Acquisitions Report;10/29/2012, Vol. 25 Issue 44, p1 

    The article reports on the acquisition of privately-held specialty pharmaceutical firm NextWave Pharmaceuticals by Pfizer Inc.

  • Pfizer Sues Dr. Reddy's Over Lipitor Patent.  // India -- West;1/1/2010, Vol. 35 Issue 6, pA21 

    The article reports on the court case filed by drug company Pfizer Inc. against Dr. Reddy's Laboratories Ltd. regarding the trade of the generic versions of anti-cholesterol medicine Lipitor in the U.S.

  • Dr. Reddy's eyes growth in Europe business.  // FRPT- Chemical Snapshot;8/31/2015, p17 

    The article discusses the intent of pharmaceutical company Dr. Reddy's Laboratories to expand its business in Europe particularly Spain, France, and Italy over the next two years.

  • Dr. Reddy's to acquire select products of Belgian firm, UCB.  // FRPT- Chemical Snapshot;4/19/2015, p14 

    The article reports that Dr. Reddy's Laboratories will purchase some products of biopharmaceutical firm UCB in Maldives, Sri Lanka, Nepal and India in April 2015.

  • Dr. Reddy's completes acquisition of UCB brands.  // FRPT- Chemical Snapshot;7/5/2015, p1 

    The article reports on the acquisition of selected UCB pharmaceutical portfolio by Dr. Reddy's Laboratories in India, Sri Lanka and Maldive to increase presence in the areas of pediatrics, dermatology and neurology.

  • Rheoscience, Dr. Reddy's Move Balaglitazone Into Phase III Trial. Sheridan, Cormac // BioWorld International;8/8/2007, Vol. 12 Issue 32, p1 

    This article reports on the Phase III clinical trial of balaglitazone, a partial agonist of peroxisome proliferator-activated receptor gamma, in patients with Type II diabetes, which is being conducted by Rheoscience A/S and Dr. Reddy's Laboratories Ltd. Balaglitazone is a member of the...

  • Dr. Reddy's Balaglitazone Data Solid in Phase III.  // Bioworld Week;1/11/2010, Vol. 18 Issue 2, p2 

    The article reports on the solid top-line data gathered by pharmaceutical companies Dr. Reddy's Laboratories Ltd. and Nordic Bioscience AS from the Phase III trial of the insulin sensitizer balaglitazone. It presents findings for the efficacy of Takeda Pharmaceuticals Co. Ltd.'s Actos in dodging...

  • LigoCyte Buyout Beats Odds; Viral 'Load' on the Front End. Moran, Nuala; Osborne, Randy // BioWorld International;10/10/2012, Vol. 17 Issue 41, p3 

    The article reports on the acquisition deal disclosed between vaccines firm LigoCyte Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd. It notes that positive results from a trial testing of LigoCyte's vaccine against one of norovirus' two strains were published in December 2011 in the "New...

  • Takeda Boosts Global Vaccine Business with LigoCyte Pharmaceuticals Acquisition. Cartwright, Heather // PharmaDeals Review;2012, Vol. 2012 Issue 10, p138 

    The article focuses on the acquisition of LigoCyte Pharmaceuticals, a U.S-based vaccine developer, by Takeda Pharmaceutical through its Takeda America Holdings subsidiary to boost its global vaccines business. It mentions that completion of the acquisition is anticipated to end by November 2012....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics